NCT00270790View on ClinicalTrials.gov

EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH HEAD AND NECK CANCER.(GCC 0202)

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

December 31, 2005

Study Completion Date

February 28, 2009

Conditions
Head and Neck Cancer
Interventions
DRUG

Amifostine

Amifostine will be given at dose of 500 mg IV within one hour before radiation

DRUG

Carboplatin

Carboplatin for 100 mg/m2 and will be administered after the taxol infusion

DRUG

Taxol

Taxol will be given at a dose of 40 mg/m2 as a 3 hour infusion dose

DEVICE

Radiotherapy

Radiation will be given at a dose of 1.8 Gy. for a total of 70.2 Gy

Trial Locations (1)

21201

University of Maryland, Baltimore

Sponsors

Collaborators (1)

MedImmune LLC
All Listed Sponsors
collaborator

MedImmune LLC

INDUSTRY

lead

Mohan Suntharalingam

OTHER

NCT00270790 - EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH HEAD AND NECK CANCER.(GCC 0202) | Biotech Hunter | Biotech Hunter